4503.T
Astellas Pharma Inc.$2,169.50
Jun 02, 2026
Revenue · FY
$2.14T
Net income
$291.54B
FY 2026
EPS · diluted
$162.22
EBITDA
$614.29B
Explain this page
Arphra AIPlain-English read on Astellas Pharma Inc.’s valuationNo ESG data on file
ESG disclosures for 4503.T aren't available yet — check back shortly.
Browse the cross-market ESG hub instead.